AI Summary
→ WHAT IT COVERS The $45 billion supplement industry operates with minimal FDA oversight under 1994's DSHEA law, allowing brain supplements to make health claims without proving efficacy through clinical trials, unlike pharmaceutical drugs requiring rigorous testing. → KEY INSIGHTS - **Supplement contamination:** Two-thirds of protein powders contain more lead per serving than daily safe limits, sometimes 10x higher. Supplement versions of galantamine ranged from 2% to 110% of labeled quantity, with one-third contaminated with gastrointestinal bacteria. - **Evidence hierarchy:** Exercise, sleep, nutrition, and social engagement provide 90% of cognitive function benefits. Supplements offer marginal gains only after optimizing these fundamentals. GLP-1 drugs show promising cognitive benefits in clinical trials, unlike most brain supplements with zero robust data. - **Legal loopholes:** Manufacturers can claim supplements maintain healthy memory or boost cognition without human studies, as long as they avoid naming specific diseases like Alzheimer's. FDA treats supplements as food, not drugs, requiring no pre-market safety testing or efficacy proof. - **Food versus pills:** Omega-3 studies show populations eating fatty fish have lower Alzheimer's rates, but omega-3 supplements show no cognitive benefit in five-year trials. Whole foods contain thousands of compounds working synergistically that isolated supplements cannot replicate effectively. → NOTABLE MOMENT A physician invested in supplements after repeated fainting episodes from low blood pressure discovered electrolyte drinks solved the problem more reliably than eating more salt, demonstrating how compliance often matters more than ingredient source for achieving health outcomes. 💼 SPONSORS None detected 🏷️ Supplement Regulation, Brain Health, FDA Policy, Dietary Supplements